This clinical trial is focused on studying a treatment for prostate cancer, specifically in cases where the cancer is locally advanced or has spread to other parts of the body, known as metastatic prostate cancer. The treatment being tested is called Debio 4228, which is a type of medication known as a gonadotropin-releasing hormone (GnRH) antagonist. This medication works by blocking certain hormones that can promote the growth of prostate cancer cells.
The purpose of the study is to explore how Debio 4228 behaves in the body and how it affects hormone levels over time. Participants in the study will receive the medication through an injection into the muscle. The study will last for several weeks, during which time participants will have regular check-ups to monitor their health and the effects of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of Debio 4228.
Throughout the study, researchers will pay close attention to how well the treatment works in lowering testosterone levels, which is a key goal in managing prostate cancer. They will also monitor any side effects or reactions at the injection site, as well as overall health indicators like blood tests and heart function. The study aims to gather important information that could help improve treatment options for people with advanced prostate cancer in the future.
Belgium 
Bulgaria 
France 
Italy 
Lithuania 
Poland 
Spain 
